Liver Res
Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Published: September 2023
Background And Aims: Many centers do not offer living donor transplants for patients in need of a liver retransplant. We aimed to study our liver retransplant outcomes using living donors and compared them with those of retransplants performed using deceased donors.
Methods: This study retrospectively analyzed all retransplants performed at our center between 2009 and 2023, and outcomes of living donor retransplants were compared with deceased donor retransplants using standard statistical tests.
Results: Between January 2009 and March 2023, a total of 77 retransplants, 60 with deceased donors and 17 with living donors, were performed. Important demographic differences between the two groups included a higher model for end-stage liver disease score in the deceased donor group (32.1 ± 6.1 . 19.4 ± 5.7, < 0.001) and a higher number of early retransplants (within 3 months of the initial transplant), which accounted for 35% of deceased donor transplants but 0 of living donor transplants ( < 0.01). Overall, the patient and graft survival rates were comparable between the two groups. The patient survival rates at 1 and 3 years after transplant were 73% and 67% in the deceased donor group and 84% and 73% in the living donor group, respectively ( = 0.57). The hospital length of stay and blood product use were both better in the living donor group. Biliary complications did not show significant different between the two groups ( = 0.33).
Conclusions: Living donors can provide acceptable outcomes for those in need of a retransplant, with results comparable to those seen with deceased donors. A systematic approach to the patient in the pre-, peri-, and post-transplantation period is important in these complicated cases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791900 | PMC |
http://dx.doi.org/10.1016/j.livres.2023.09.003 | DOI Listing |
Transpl Int
March 2025
Department of General Surgery, Demiroglu Bilim University and Group Florence Nightingale Hospital, Istanbul, Türkiye.
Kidney donation is a safe procedure for carefully screened donors. The growing shortage of organs and improved survival rates among recipients of living donor transplants have broadened the criteria for acceptable living donors, including older individuals and those with pre-existing health conditions. Consequently, ensuring both the short- and long-term safety of living donors is of paramount importance.
View Article and Find Full Text PDFPediatr Transplant
May 2025
Department of General Surgery, Başkent University Faculty of Medicine, Ankara, Turkey.
Background: Inborn errors of metabolism (IEMs) are inherited diseases causing significant morbidity and mortality, particularly in childhood. Liver transplantation (LT) can be curative or partially effective for these diseases. LT for IEMs has increased, making IEMs the second most common reason for pediatric LT after biliary atresia.
View Article and Find Full Text PDFAm J Transplant
March 2025
Histocompatibility and Infectious Disease Testing Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI. Electronic address:
Unexpected transmission of donor-derived diseases, including infections and malignancies, through organ transplantation are occasionally observed and reported. Subclinical, or otherwise undiagnosed, hematological malignancies in potential donors are rare events and typically not identifiable via standard donor evaluation or laboratory testing. Flow cytometric crossmatching (FCXM) is a specialized assay routinely performed in clinical histocompatibility laboratories for the evaluation of immunological compatibility between the recipients and the organ donors through the detection of donor-specific antibodies.
View Article and Find Full Text PDFJ Immunol
February 2025
HIV Immunopathogenesis Laboratory, BEAT-HIV Delaney Collaboratory, Wistar Institute, Philadelphia, PA, United States.
Natural killer (NK) cells can efficiently mediate antibody-dependent cellular cytotoxicity (ADCC) of antibody coated target cells via the low-affinity Fc-receptor, CD16, but cannot retain antibodies over time. To increase antibody retention and facilitate targeted ADCC, we genetically modified human NK cells with the high-affinity Fc receptor, CD64, so that we could preload them with HIV-specific broadly neutralizing antibodies (BNAbs) and enhance their capacity to target HIV-infected cells via ADCC. Purified NK cells from the peripheral blood of control donors or persons living with HIV were activated with interleukin (IL)-2/IL-15/IL-21 cytokines and transduced with a lentivirus encoding CD64.
View Article and Find Full Text PDFFront Public Health
March 2025
Department of Health Services Management & Organisation, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Living kidney donors voluntarily donate one of their kidneys to someone suffering from end-stage kidney disease. Transplantation is a life-saving opportunity for these patients and generally provides an increase in quality of life. A major goal of research and practice related to living kidney donation concerns the safety of the donor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.